Cytokines, Chemokines & Receptors

Cat. No.

AT0863

Anti-IL-15 Antibody (DISC0280)

Synonyms: DISC0280

The Anti-IL-15 Antibody (DISC0280) is a recombinant human monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically designed to target interleukin-15 (IL-15). This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and has a predicted molecular weight of 145 kDa. For isotype control purposes, the Human IgG1 kappa, Isotype Control is recommended. This product is ideal for research applications focusing on the biological activities and pathological roles of IL-15.

Cat. No.

AT0864

CAS No.

2865822-82-6

Denikitug

Denikitug is a chimeric antibody of the IgG1κ subtype that specifically targets CCR8. For experimental control purposes, Human IgG1 kappa Isotype Control is recommended.

Cat. No.

AT0880

CAS No.

945781-29-3

Placulumab

Synonyms: ART621; CEP-37247; PN0621

Placulumab (ART621) is a monoclonal antibody targeting tumor necrosis factor alpha (TNF α), exhibiting potent anti-inflammatory properties. This biologic is designed for the investigation and potential treatment of various inflammatory disorders, including arthritis, where TNF α plays a critical role in disease pathogenesis. Placulumab's specificity for TNF α makes it a valuable tool in research focused on elucidating the mechanisms of inflammation and in clinical settings addressing TNF α-mediated conditions.

Cat. No.

AT0884

CAS No.

2648456-30-6

Galvokimig

Synonyms: UCB-9741

Galvokimig is a monoclonal antibody designed to target and neutralize interleukin 13 (IL-13), interleukin 17A (IL-17A), albumin (ALB), and interleukin 17B (IL-17B). This antibody is engineered for high specificity and affinity, making it suitable for use in research studies investigating the roles and interactions of these cytokines in various inflammatory and autoimmune conditions. Galvokimig can be applied in a range of experimental setups, including immunoassays, functional studies, and as a potential therapeutic strategy model.

Cat. No.

AT0891

CAS No.

2851855-89-3

Cafelkibart

Cafelkibart is a chimeric IgG1κ monoclonal antibody specifically designed to target CCR8. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0892

CAS No.

1791411-57-8

Lutikizumab

Synonyms: ABT-981

Lutikizumab (ABT-981) is a dual variable domain immunoglobulin designed to specifically target and inhibit both interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β). This monoclonal antibody functions by binding to these cytokines, effectively neutralizing their activity and mitigating their pro-inflammatory effects. Lutikizumab is primarily utilized in research focused on understanding and treating osteoarthritis, providing a valuable tool for investigating the role of IL-1 in inflammatory processes associated with this degenerative disease.

Cat. No.

AT0893

Infliximab (Anti-TNF-α)

Synonyms: Avakine (Anti-TNF-α; CT-P13 (Anti-TNF-α

Infliximab, marketed under the name Avakine, is a chimeric monoclonal IgG1 antibody that selectively targets and binds to tumor necrosis factor alpha (TNF-α). By inhibiting the interaction between TNF-α and its receptors (TNFR1 and TNFR2), Infliximab effectively modulates inflammatory responses. This antibody is widely utilized in research focused on autoimmune diseases, chronic inflammatory conditions, and diabetic neuropathy, offering significant potential for elucidating disease mechanisms and therapeutic interventions.

Cat. No.

AT0895

CAS No.

915404-94-3

Carlumab

Synonyms: CNTO 888

Carlumab (CNTO 888) is a human monoclonal antibody that exhibits high affinity for chemokine ligand 2 (CCL2). This antibody is particularly utilized in the study of cancer mechanisms, with a focus on prostate cancer research. Carlumab's ability to target CCL2 makes it a valuable tool for investigating the role of this chemokine in tumor microenvironments and its potential impact on cancer progression and metastasis.

Cat. No.

AT0898

CAS No.

910649-32-0

Anrukinzumab

Synonyms: IMA-638

Anrukinzumab (IMA-638) is a humanized monoclonal antibody that targets interleukin-13 (IL-13), a cytokine implicated in the pathogenesis of several inflammatory conditions. This antibody has demonstrated efficacy in reducing lung inflammation in cynomolgus monkey models, highlighting its potential utility in pulmonary research. Anrukinzumab is suitable for use in investigations into the mechanisms and treatment of diseases such as ulcerative colitis and asthma, providing a valuable tool for both basic research and therapeutic development.

Cat. No.

AT0899

CAS No.

1533403-95-0

Lokivetmab

Synonyms: Anti-Canine IL31 Recombinant Antibody

Lokivetmab is a recombinant monoclonal antibody specifically targeting canine interleukin-31 (IL-31). This antibody is utilized primarily in the study of atopic dermatitis in dogs, providing a valuable tool for understanding the pathophysiology of this condition and the role of IL-31 in canine allergic responses.

Cat. No.

AT0900

R707

R707 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets CCR7/CD197, a chemokine receptor involved in the regulation of leukocyte migration. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.36 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Cat. No.

AT0902

ABT-325

ABT-325 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting interleukin-18 (IL-18). This antibody is composed of a human IgG1 type heavy chain and a human kappa (huκ) type light chain. ABT-325 has a predicted molecular weight of 146.28 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is suitable for a range of immunological applications where IL-18 activity modulation is investigated.

Cat. No.

AT0903

CAS No.

2377482-36-3

Plonmarlimab

Synonyms: TJ003234; TJM2

Plonmarlimab (TJ003234) is a monoclonal antibody targeting Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). This antibody is utilized in the investigation of inflammatory conditions such as rheumatoid arthritis, as well as in the study of immune response mechanisms in COVID-19. Plonmarlimab offers a specific tool for researchers exploring the role of GM-CSF in disease pathology and therapeutic intervention.

Cat. No.

AT0908

CAS No.

1610761-46-0

Plozalizumab

Synonyms: MLN-1202

Plozalizumab (MLN-1202) is a humanized monoclonal antibody that selectively targets the CCR2 (C-C chemokine receptor type 2) receptor. This specificity makes it a valuable tool for investigating the role of CCR2 in malignant melanoma, providing insights that may contribute to the development of targeted therapies for this aggressive cancer.

Cat. No.

AT0911

CAS No.

1229575-09-0

Lenzilumab

Synonyms: KB 003

Lenzilumab (KB 003) is a humanized monoclonal antibody specifically designed to neutralize colony-stimulating factor 2 (CSF2), also known as granulocyte-macrophage colony-stimulating factor (GM-CSF). This antibody is utilized in research focused on COVID-19 and myelomonocytic leukemias, including chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Its targeted action against CSF2/GM-CSF makes it a valuable tool for understanding and potentially modulating inflammatory and immune responses in these disease states.

Cat. No.

AT0912

CAS No.

2894138-72-6

Rilogrotug

Rilogrotug is a human monoclonal antibody of the IgG1κ subtype that specifically targets GDF15 (Growth Differentiation Factor 15). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0921

CAS No.

1129435-60-4

Gevokizumab

Gevokizumab is a potent monoclonal antibody that targets interleukin-1 beta (IL-1β), employing an allosteric mechanism to modulate IL-1β signaling negatively. This antibody selectively reduces the binding affinity of IL-1β to its signaling receptor, interleukin-1 receptor type I (IL-1RI), rather than affecting the interaction with the IL-1 counter-regulatory decoy receptor, interleukin-1 receptor type II (IL-1RII). This specificity in modulation facilitates the detailed study of IL-1β signaling pathways and their physiological and pathological roles. Gevokizumab is instrumental in research focused on inflammation and immune response, offering potential therapeutic insights into diseases mediated by IL-1β.

Cat. No.

AT0926

CAS No.

2981469-90-1

Tilrekimig

Tilrekimig is a monoclonal antibody engineered to specifically target human interleukin 4 (IL-4), interleukin 13 (IL-13), and thymic stromal lymphopoietin (TSLP). This antibody is of significant interest for the study of allergic and inflammatory disorders, including asthma and atopic dermatitis. Its specificity for these cytokines makes it a valuable tool in the investigation of the underlying mechanisms of these diseases and the development of targeted therapies.

Cat. No.

AT0929

CAS No.

2243320-83-2

Vixarelimab

Synonyms: KPL-716

Vixarelimab (KPL-716) is a human monoclonal antibody targeting the beta chain of the oncostatin M (OSM) receptor. By binding to this subunit, Vixarelimab effectively inhibits signaling pathways mediated by interleukin-31 (IL-31) and OSM. This antibody is particularly useful in research focused on inflammatory skin conditions, including atopic dermatitis and prurigo nodularis, providing a valuable tool for investigating the molecular mechanisms underlying these diseases and potentially guiding therapeutic interventions.

Cat. No.

AT0937

CAS No.

2102543-86-0

Imsidolimab

Synonyms: ANB 019

Imsidolimab (ANB 019) is a high-affinity humanized monoclonal antibody that targets IL-36 receptor (IL-36R), effectively antagonizing IL-36 cytokine signal transduction. This antibody is designed for potential therapeutic use in managing generalized pustular psoriasis (GPP) and various other inflammatory skin conditions. Its specificity for IL-36R makes it a valuable tool for research and treatment development in dermatological inflammation.

Cat. No.

AT0943

NI-0701

NI-0701 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target CCL5/RANTES. This antibody is composed of a human IgG2 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of 145 kDa. For experimental control purposes, the recommended isotype control is Human IgG2 kappa, Isotype Control. NI-0701 is applicable in research focused on the biological roles and therapeutic targeting of the chemokine CCL5/RANTES.

Cat. No.

AT0947

CAS No.

2229685-51-0

Avizakimab

Synonyms: BOS161721

Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody specifically designed to target interleukin-21. This therapeutic protein is engineered to bind selectively to interleukin-21, a cytokine implicated in the pathogenesis of various autoimmune diseases, thereby modulating immune responses and providing potential therapeutic benefits in disorders characterized by excessive or aberrant cytokine activity.

Cat. No.

AT0960

CAS No.

2412004-88-5

Livmoniplimab

Synonyms: ABBV-151; ARGX-115

Livmoniplimab (ABBV-151) is a monoclonal antibody targeting the GARP/TGF-β1 complex, effectively inhibiting the release of active transforming growth factor-beta 1 (TGF-β1). Demonstrating significant anti-tumor activity in murine models of colon cancer, Livmoniplimab is primarily utilized in research focused on locally advanced or metastatic solid tumors. This antibody serves as a crucial tool in the investigation of TGF-β1's role in tumor microenvironments and cancer progression, offering potential insights into therapeutic strategies for solid tumors.

Cat. No.

AT0964

CAS No.

428863-50-7

Certolizumab pegol

Synonyms: Certolizumab; CDP870

Certolizumab pegol is a recombinant, polyethylene glycolylated antigen-binding fragment derived from a humanized monoclonal antibody. It selectively targets and neutralizes tumor necrosis factor-alpha (TNF-α), making it highly relevant for studies in rheumatoid arthritis and Crohn's disease. This specificity for TNF-α provides a critical tool for researchers investigating the pathophysiology and therapeutic interventions of these inflammatory disorders.

Cat. No.

AT0966

CAS No.

2622254-57-1

Bempikibart

Synonyms: ADX-914

Bempikibart (ADX-914) is a humanized monoclonal antibody targeting the interleukin-7 receptor alpha (IL-7Rα). Designed for research purposes, it is utilized primarily in the study of inflammatory processes. This antibody may serve as a valuable tool in investigating the role of IL-7Rα in immune response modulation and inflammation.